Allogene Therapeutics Appoints Dr. Zachary Roberts as New CEO, Replacing Dr. David Chang
Summary
Allogene Therapeutics announced an executive leadership transition, appointing Dr. Zachary Roberts, current EVP of R&D and CMO, as its new President and CEO, effective July 1, 2026, with Dr. David Chang transitioning to a non-employee director role.
Key Events
-
New CEO Appointed
Dr. Zachary Roberts, currently Executive Vice President, Research and Development, and Chief Medical Officer, has been appointed President and Chief Executive Officer, effective July 1, 2026.
-
Leadership Transition
Dr. David Chang will step down as President and CEO on June 30, 2026, but will remain on the Board of Directors as a non-employee director.
-
New CEO Compensation Details
Dr. Roberts' new compensation package includes an annualized base salary of $680,000, an annual target performance cash incentive of 60% of his base salary, an option to purchase 476,190 shares, and a restricted stock unit award of 134,530 shares.
-
Board Appointment
Dr. Roberts was also appointed to the Board as a Class I director, effective July 1, 2026.
Analysis
This filing announces a significant leadership transition at Allogene Therapeutics, with the internal promotion of Dr. Zachary Roberts, previously EVP of Research and Development and Chief Medical Officer, to President and CEO. This move signals a potential continuation of the company's scientific and clinical development strategy, leveraging Dr. Roberts' extensive background in oncology and cell therapy from his prior roles at Kite and Amgen. The outgoing CEO, Dr. David Chang, will remain on the Board as a non-employee director, providing some continuity during this transition. The new CEO's compensation package, including substantial equity awards, aligns his incentives with long-term shareholder value.
At the time of this filing, ALLO was trading at $2.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $776.6M. The 52-week trading range was $0.98 to $4.46. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.